While treatment of localized cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is based on surgery, brachytherapy, which delivers a high dose of radiation to tumor tissue while sparing healthy tissue, is an alternative. Since the withdrawal of iridium wires from the market, brachytherapy has mainly been performed with high-dose-rate iridium-192 (HDR). This study evaluated the efficacy of HDR brachytherapy in terms of local control, survival, toxicity, and quality of life in patients with facial periorificial cutaneous SCC or BCC treated in our center between 2015 and 2021. Sixty-seven patients were treated for SCC (n= 49) or BCC (n= 18), on the nose (n= 29), lip (n= 28), eyelid (n= 7), or ear (n= 3). The majority had Tis or T1 tumors (73.1%). After a median follow-up of 28 months, 8 patients had a local recurrence. The local control rate at 3 years was 87.05% (95% CI 74.6–93.7). All patients developed grade 1–2 acute radio-mucositis or radiodermatitis and one experienced reversible grade 3 acute radio-mucositis. Of the 27 patients who completed the quality-of-life questionnaire, 77.8% recommended the treatment. This study confirms that HDR brachytherapy for facial cutaneous carcinomas provides good local control, good tolerance, and satisfactory functional outcome.
对于局部皮肤鳞状细胞癌（SCC）和基底细胞癌（BCC）的治疗，虽然手术是主要手段，但近距离放射治疗（即近距离放疗）作为一种替代方案，能够在向肿瘤组织提供高剂量辐射的同时保护健康组织。自铱丝退出市场后，近距离放疗主要采用高剂量率铱-192（HDR）进行。本研究评估了2015年至2021年间在我中心接受治疗的颜面部孔周皮肤SCC或BCC患者中，HDR近距离放疗在局部控制、生存率、毒副作用及生活质量方面的疗效。共67例患者接受了治疗，其中SCC 49例，BCC 18例，病变部位包括鼻部（29例）、唇部（28例）、眼睑（7例）和耳部（3例）。大多数患者为Tis或T1期肿瘤（73.1%）。中位随访28个月后，8例患者出现局部复发。3年局部控制率为87.05%（95% CI 74.6–93.7）。所有患者均出现1-2级急性放射性黏膜炎或放射性皮炎，1例出现可逆性3级急性放射性黏膜炎。在完成生活质量问卷的27例患者中，77.8%推荐该治疗方案。本研究证实，HDR近距离放疗治疗颜面部皮肤癌具有良好的局部控制效果、耐受性及满意的功能预后。
肿瘤(癌症)患者之家